Press Releases

Featured
Survey of US Optometrists Reveals Large Number of Untreated Keratoconus Patients
Survey of US Optometrists Reveals Large Number of Untreated Keratoconus Patients

Jonathan H. Talamo, MD, Chair of the Board at Epion Therapeutics, Presents Optometric Survey Results at Eyecelerator @ AAO 2024

Epion Therapeutics' CMO, Michael W. Belin, MD, Shares Phase 3 Updates at Eyecelerator during ASCRS Conference
Epion Therapeutics' CMO, Michael W. Belin, MD, Shares Phase 3 Updates at Eyecelerator during ASCRS Conference
Epion Therapeutics Initiates Phase 3 Clinical Trials for Minimally-Invasive Keratoconus Treatment
Epion Therapeutics Initiates Phase 3 Clinical Trials for Minimally-Invasive Keratoconus Treatment
CXL Ophthalmics Announces New Name and Vision as Epion Therapeutics
CXL Ophthalmics Announces New Name and Vision as Epion Therapeutics
CXL Ophthalmics CEO Michael D. Webb to Present at 2023 BIO International Convention
CXL Ophthalmics CEO Michael D. Webb to Present at 2023 BIO International Convention
Dr. Ken Beckman Shares Insights on Groundbreaking Epithelium-On Cross-Linking Treatment at ASCRS Conference
Dr. Ken Beckman Shares Insights on Groundbreaking Epithelium-On Cross-Linking Treatment at ASCRS Conference
CXL Ophthalmics’ CMO To Deliver Plenary Session at 1st Annual International Keratoconus Academy Symposium
CXL Ophthalmics’ CMO To Deliver Plenary Session at 1st Annual International Keratoconus Academy Symposium
CXL Ophthalmics Appoints Tiffany Haynes as Vice President of Clinical Operations
CXL Ophthalmics Appoints Tiffany Haynes as Vice President of Clinical Operations
CXL Ophthalmics Appoints Jonathan Talamo, MD, as Chair of the Board
CXL Ophthalmics Appoints Jonathan Talamo, MD, as Chair of the Board
CXL Ophthalmics Announces $32 Million Series A Investment Round Led by AXA IM Alts, Through its Global Health Private Equity Strategy
CXL Ophthalmics Announces $32 Million Series A Investment Round Led by AXA IM Alts, Through its Global Health Private Equity Strategy
CXL Ophthalmics Publishes Results of EpiSmart® Cross-Linking Phase 2 Clinical Trial for Keratoconus in Cornea
CXL Ophthalmics Publishes Results of EpiSmart® Cross-Linking Phase 2 Clinical Trial for Keratoconus in Cornea

“The results of this study demonstrate the promise of our approach to cross-linking in halting the progression of keratoconus in patients and restoring vision with a minimally-invasive process”

CXL Ophthalmics Announces Results of Successful Phase 2 Clinical Trial in Epi-On Cross-linking for Keratoconus
CXL Ophthalmics Announces Results of Successful Phase 2 Clinical Trial in Epi-On Cross-linking for Keratoconus
CXL Ophthalmics Granted Patents on UV-A Device for Transepithelial (Epi-on) Corneal Cross-linking
CXL Ophthalmics Granted Patents on UV-A Device for Transepithelial (Epi-on) Corneal Cross-linking
CXL Ophthalmics Publishes Data Demonstrating Benefits of Ribostat™ for Transepithelial Cross-linking
CXL Ophthalmics Publishes Data Demonstrating Benefits of Ribostat™ for Transepithelial Cross-linking
CXL Ophthalmics Appoints Jonathan H. Talamo, MD to its Board of Managers
CXL Ophthalmics Appoints Jonathan H. Talamo, MD to its Board of Managers
Phase 2 Enrollment Complete
Phase 2 Enrollment Complete
Ribostat™ Research Presented at ARVO 2019
Ribostat™ Research Presented at ARVO 2019
EpiSmart™ Clinical Data Published in JCRS
EpiSmart™ Clinical Data Published in JCRS
EpiPrep™ Patent Is Issued
EpiPrep™ Patent Is Issued
EpiSmart™ Patents Issued
EpiSmart™ Patents Issued